Amyotrophic lateral sclerosis (ALS) is a progressively debilitating disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of…
Since 2018, four novel calcitonin gene-related peptide (CGRP)-targeting monoclonal antibodies (MAbs)—Novartis / Amgen’s Aimovig, Eli Lilly’s Emgality, Teva’s Ajovy, and Lundbeck’s Vyepti…
A handful of newer disease-modifying therapies (DMTs) for multiple sclerosis (MS)—Novartis’s Mayzent, Bristol Myers Squibb’s Zeposia, Novartis’s Kesimpta, and Janssen’s Ponvory—have…
Clarivate Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of asthma for each country, as well…
TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while newer biologics (i.e., Takeda’s…
Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…
A growing number of clinically unique immunomodulatory disease-modifying therapies (DMTs) are approved for the treatment of relapsing forms of multiple sclerosis (MS), the most prevalent form of…
Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the availability of LAMAs (e.g., Boehringer-…
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…
Myasthenia gravis (MG) is an acquired disorder of neuromuscular transmission, which occurs due to the production of pathogenic autoantibodies that bind to components of the neuromuscular junction,…
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. While…
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more-potent biologics or targeted…
The wet age-related macular degeneration (AMD) market in the United States is unique given that the key approved therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea, and Novartis’s…
Dyslipidemia is a key modifiable risk factor for cardiovascular disease (CVD), which is primarily managed by statin therapy. With positive CV outcomes data for certain nonstatin therapies including…
Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses, and the treatment landscape is entrenched with targeted agents. Roche’s Rituxan, Janssen / AbbVie’s…